Peptic ulcer disease

Current Opinion in Gastroenterology

Volumn 22, Issue 6, 2006, Pages 607-611

  Louw, Japie A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Helicobacter pylori; Nonsteroidal anti inflammatory drugs; NSAIDs; PPIs; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; IBUPROFEN; LEVOFLOXACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARECOXIB; PROTON PUMP INHIBITOR; RIFABUTIN; ROFECOXIB; TICLOPIDINE; VALDECOXIB;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COLORECTAL ADENOMA; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENTEROPATHY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART PROTECTION; HELICOBACTER PYLORI; HUMAN; INFECTION; LUNG DISEASE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MYOCARDIAL DISEASE; PEPTIC ULCER; POSTOPERATIVE PAIN; PUBLICATION; REVIEW; STOMACH DISEASE; STOMACH HEMORRHAGE; ULCER; ULCEROGENESIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DYSPEPSIA; ENZYME INHIBITORS; HELICOBACTER INFECTIONS; HUMANS; PEPTIC ULCER; PROGNOSIS; PROTON PUMPS;

EID: 33750374254     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000245532.12648.aa     Document Type: Review

References (45)

1. Phull PS, Salmon CA, Park KGM, Rapson T, et al. Age threshold for endoscopy and risk of missing upper gastrointestinal malignancy: data from the Scottish audit of gastric and oesophageal cancer. Aliment Pharmacol Ther 2006; 23:229-233.
2. Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the clinical history distinguish between functional and organic dyspepsia? JAMA 2006; 295:1566-1576.
3. Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006; 130:296-303.
4. Longstreth GF. Functional dyspepsia: managing the conundrum. N Engl J Med 2006; 354:791-793.
5. Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005; 128:1838-1844.
6. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esopmeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005; 100:1949-1956.
7. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330:568-575.
8. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: proton pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay. Results from the Cochrane collaboration. Aliment Pharmacol Ther 2005; 22:169-174.
9. Williams C, McColl KEL. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006; 23:3-10.
10. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital patients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33-38.
11. •] have conflicting results regarding the association between PPI use and the risk of developing C. difficile diarrhoea. The designs are not ideal and results are conflicting, but they should raise awareness of this potentially important association.
12. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989-2995. This is another of three studies with conflicting results regarding the association between PPI use and the risk of developing C. difficile diarrhoea. The designs are not ideal, and results are conflicting but they should raise awareness of this potentially important association.
13. Press release. The Nobel Prize in Physiology or Medicine 2005. Stockholm: The Nobel Assembly at Karolinska Institutet; 3 October 2005. http:// www.nobelprize.org/medicine/laureates/2005/press.html.[Accessed: May 2006]
14. Chiorean MV, Locke GR, Zinsmeister AR, et al. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. Am J Gastroenterol 2002; 97:3015-3022.
15. Vakil N. Helicobacter pylori treatment: a practical approach. Am J Gastroenterol 2006; 101:497-499.
16. Gisbert JP, De la Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23:35-44.
17. Gisbert JP, Castro-Fernandez M, Bermejo F, et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006; 101:243-247.
18. Borody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutin-containing "rescue therapy" for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23:481-488.
19. Suzuki T, Matsushima M, Masui A, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura: a randomized controlled trial. Am J Gastrenterol 2005; 100:1265-1270.
20. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528.
21. Mukherjee DM, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
22. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351:1709-1711.
23. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal cancer chemoprevention trial. N Engl J Med 2005; 352:1092-1102.
24. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080.
25. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-II inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-1091.
26. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective nonsteroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365:475-481.
27. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyco-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330:1366.
28. Oberholzer-Gee F, Inamdar N. Merck's recall of rofecoxib: a strategic perspective. N Engl J Med 2004; 351:2147-2149.
29. Psaty BM, Furberg CD. COX-2 inhibitors: lessons in drug safety. N Engl J Med 2005; 352:1133-1135.
30. Topol EJ. Failing the public health: rofecoxib, Merck and the FDA. N Engl J Med 2004; 351:1707-1709.
31. Waxman HA. The lessons of Vioxx: drug safety and sales. N Engl J Med 2005; 352:2576-2578.
32. Drazen JM. COX-2 inhibitors: a lesson in unexpected problems. N Engl J Med 2005; 352:1131-1132.
33. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528." N Engl J Med 2005; 353:2813-2814.
34. Bombardier C, Laine L, Burgos-Vargas R, et al. Response to expression of concern regarding VIGOR study. N Engl J Med 2006; 354:1196-1198.
35. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using nonselective NSAID and COX-2 inhibitors. Am J Gastroenterol 2006; 101:701-710.
36. Goldstein JL, Johanson JF, Suchower LJ, Brown KA. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomised trial. Am J Gastroenterol 2005; 100:2650-2657.
37. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22:795-801.
38. Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2-selective inhibition: a double-blind trial. Gastroenterology 2004; 127:395-402.
39. Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Upper gastrointestinal haemorrhage associated with low-dose aspirin and antithrombotic drugs: a 6-year analysis and comparison with nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2005; 22:285-289.
40. Chan FKL, Ching JYL, Hung LCT, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352:238-244. This important study demonstrated that clopidogrel is not a safe alternative to aspirin as cardioprophylaxis in patients at higher risk for bleeding from peptic ulcer disease. It demonstrated that aspirin combined with PPI (co-therapy) represents a safer alternative.
41. Ibanez L, Vidal X, Vendrell L, et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006; 23:235-242.
42. •] demonstrated a strikingly high incidence of small bowel 'abnormalities/injury' in patients taking NSAIDs. The authors did not address the clinical significance of these findings and suggested that COX-2 selective agents, but not PPI co-therapy, protect against such damage.
43. •] demonstrated a strikingly high incidence of small bowel 'abnormalities/injury' in patients taking NSAIDs. The authors did not address the clinical significance of these findings and suggested that COX-2 selective agents, but not PPI co-therapy, protect against such damage.
44. •] demonstrated a strikingly high incidence of small bowel 'abnormalities/injury' in patients taking NSAIDs. The authors did not address the clinical significance of these findings and suggested that COX-2 selective agents, but not PPI co-therapy, protect against such damage.
45. Fiorucci S, Santucci L, Gresele P, et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003; 124:600-607.